Article (Scientific journals)
Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate
Manette, Christine; Collette, Julien; Sarlet, Nathalie et al.
2006In Current Medicinal Chemistry, 13 (13), p. 1585-1590
Peer Reviewed verified by ORBi
 

Files


Full Text
Comprehensive therapy in osteoporosis using a single drug.pdf
Publisher postprint (737.4 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
osteoporosis; treatment; fractures; strontium ranelate
Abstract :
[en] In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated rat osteoclast, a preincubation of bone slices with strontium ranclate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. In a phase 11 dose ranging trial Strontium ranclate (500 mg. 1000 mg, 2000 mg/day) or placebo were given to 353 postmenopausal women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study. the annual increase in lumbar BMD of the group receiving 2000 mg of strontium ranclate was + 7.3%. a significant increase in bone alkaline phosphatase, over a 6-month period and a significant decrease in N-telopeptide crosslinks throughout the 2-year period were seen. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. The primary analysis of the SOTI study, evaluatine the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patient experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture by 16% in the group treated with strontium ranclate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture by 36% was also demonstrated in the patients at high risk of hip fracture (age >= 74 years and Femoral Neck T score <=-2.4 according to NHANES normative value).
Disciplines :
Chemistry
Biochemistry, biophysics & molecular biology
Pharmacy, pharmacology & toxicology
Author, co-author :
Manette, Christine ;  Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique
Collette, Julien ;  Centre Hospitalier Universitaire de Liège - CHU > Chimie médicale
Sarlet, Nathalie ;  Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Tancredi, Annalisa ;  Université de Liège - ULiège > Département des sciences de la santé publique > Ecole de santé publique
Zegels, Brigitte ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate
Publication date :
2006
Journal title :
Current Medicinal Chemistry
ISSN :
0929-8673
eISSN :
1875-533X
Publisher :
Bentham Science Publ Ltd, Sharjah, United Arab Emirates
Volume :
13
Issue :
13
Pages :
1585-1590
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 04 February 2011

Statistics


Number of views
112 (4 by ULiège)
Number of downloads
3 (3 by ULiège)

Scopus citations®
 
6
Scopus citations®
without self-citations
6
OpenCitations
 
4

Bibliography


Similar publications



Contact ORBi